With January here, many people are setting health and fitness goals for the New Year, including trying to lose weight. Regular exercise, gym sessions, and a balanced, nutritious diet are essential for overall well-being and can support weight loss. For some, though, these efforts may not be enough. In certain cases, medications that support weight loss can be an option. These are generally prescribed for people with type 2 diabetes or for those who have struggled to lose weight through lifestyle changes alone. They are not meant only for people who “cannot” lose weight, but rather serve as an additional tool when other methods haven’t been enough.What Are GLP-1 Agonists?GLP-1 agonists are medicines like tirzepatide and semaglutide, often sold under brand names such as Mounjaro, Ozempic, or Wegovy. They are typically prescribed to adults with type 2 diabetes or for long-term weight management in specific cases. These medications work by slowing the emptying of the stomach and mimicking gut hormones, helping control blood sugar levels and reducing appetite, as per Mirror.NHS Alert for Patients Taking MounjaroFor those eligible for these injections and prescribed them by a GP, there is an important alert from the NHS. This mainly concerns people who are also taking other medications, such as the contraceptive pill or Hormone Replacement Therapy (HRT). An ‘important notice’ on the NHS website advises that these injections can affect how well the pill and HRT work in the body.The NHS explains: “Many patients are now using weight loss medicines like Tirzepatide (Mounjaro) or Semaglutide (Ozempic, Wegovy, Rybelsus) — either for diabetes or privately for weight loss. These medications work partly by slowing how quickly your stomach empties, which can change how effectively other medicines (like the contraceptive pill or HRT tablets) are absorbed.”Warning Points If You Take the Contraceptive PillTirzepatide (Mounjaro) may reduce the effectiveness of any oral contraceptive, including the Progesterone-Only Pill. The NHS recommends that you:Use a non-oral contraceptive method (such as a coil or implant)Or use a barrier method (like condoms) for four weeks after starting or increasing the doseThe NHS adds: “Use extra protection (like condoms) if you have vomiting or diarrhoea, and follow the missed pill rules (see your pill’s patient information leaflet) if you vomit within three hours of taking it or have diarrhoea lasting more than 24 hours.”For Semaglutide and similar medications, the NHS says they do not seem to reduce the pill’s effectiveness. However, side effects like vomiting or diarrhoea can still affect absorption.“So, use additional protection (like condoms) if you experience vomiting or diarrhoea, and follow the missed pill instructions (see the patient leaflet) if vomiting occurs within three hours of taking the pill or diarrhoea lasts over 24 hours,” the NHS advises. “For more details, see: Patient Information GLP-1 Agonists and Contraception.”Non-Oral Contraception and Safety The NHS confirms that GLP-1 agonists do not impact non-oral contraception methods. Using options like the coil (IUD), implant, or injection is safe without extra precautions when on a GLP-1 agonist. If you are considering changing your contraceptive method, discuss it with your doctor first.The health service also stresses: “GLP-1 agonists should not be used during pregnancy. Effective contraception is essential while taking these medications. If you become pregnant while on these medicines, contact your doctor immediately. GLP-1 agonists should also be stopped several weeks before trying to conceive.”If you are using Hormone Replacement Therapy (HRT):This guidance applies if your HRT contains progesterone in tablet form, such as:Progesterone or UtrogestanNorethisteroneMedroxyprogesterone acetateAs per the NHS, there are concerns that medicines like tirzepatide (Mounjaro) and semaglutide may interfere with how well these tablets are absorbed by the body. According to the NHS, reduced absorption can result in irregular bleeding and may weaken protection of the womb lining, which could increase the risk of endometrial cancer.